Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL29625842 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL405854 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL41748 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7141021 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1377516 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL405853 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7137387 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL6052999 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL405855 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543502 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137835-A1 | Tramadol Hydrochloride Solution | ROSEMONT PHARMACEUTICALS LLC | 2021-05-13 | — | — | US | disclosed |
| US-9427435-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150141461-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8871791-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130338166-A1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2114147-B9 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2486921-A1 | Reducing Side Effects of Tramadol | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2114147-B1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120018333-A1 | Reducing Side Effects of Tramadol | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| WO-2010098897-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | TEIKOKU PHARMA USA, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216842-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2114147-A2 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI Biosciences, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080261991-A1 | comprising coadministering an effective amount of a phosphodiesterase inhibitor (PDE); reducing the incidence of newly-discovered side effects related to sexual function in human males | DMI BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008100933-A2 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |